This subtopic includes a selection of definitions and standard commercial clauses for use in agreements in the life sciences sector.
For boilerplate commercial clauses and standard definitions which may be used in life sciences agreements, see: Boilerplate clauses—overview and Definitions—overview.
For a summary of the law, guidance and practice in relation to the execution of documents, along with standard execution clauses, see: Execution—overview.
For examples of definitions which are frequently used in life sciences agreements, see Precedents:
Applicable Laws and Medical Product Law definitions—life sciences
Clinical trial laws definition—life sciences
Derivatives definition—life sciences
EU Notified Body and UK Approved Body definition—life sciences
Exploit definition—life sciences
Good Clinical Practice (GCP) definition—life sciences
Good Laboratory Practice (GLP) definition—life sciences
Governmental Entity definition—life sciences
Industry Practice definition—life sciences
Material definition—life sciences
Principal investigator (PI) definition—life sciences
Product definition—life sciences
Progeny definition—life sciences
Regulatory Documentation definition—life sciences
Regulatory Approvals definition—life sciences
Regulatory Authority definition—life sciences
Intellectual...
To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.
**Trials are provided to all LexisNexis content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisNexis services please email customer service via our online form. Free trials are only available to individuals based in the UK, Ireland and selected UK overseas territories and Caribbean countries. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
This week’s edition of Life Sciences weekly highlights includes the key Autumn Budget 2026 announcements for the life sciences sector, covering new...
The Department of Health and Social Care (DHSC) has announced new UK-wide restrictions banning sales of nicotine-free vapes and nicotine products,...
In the Autumn Budget 2026, delivered on 28 October 2026, the Chancellor of the Exchequer, John Healey MP, announced plans for new regulatory powers...
The European Commission’s Directorate-General for Environment has summarised a 2025 report on environmental protection in EU pharmaceutical reform....
Priority between loss reliefs in loss making companiesWhy does it matter?A company that is a member of a group and has incurred any of the types of losses available for surrender by way of group relief may, without any further rules, have more than one way in which to use the loss. There are a
Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid
If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit
Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an
0330 161 1234